{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:33:10Z","timestamp":1761895990100},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1097\/inf.0000000000000630","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T21:44:12Z","timestamp":1417556652000},"page":"e113-e118","source":"Crossref","is-referenced-by-count":26,"title":["Immunogenicity and Safety of Meningococcal C Conjugate Vaccine in Children and Adolescents Infected and Uninfected with HIV in Rio de Janeiro, Brazil"],"prefix":"10.1097","volume":"34","author":[{"given":"Ana Cristina C.","family":"Frota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucimar G.","family":"Milagres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee H.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Menna Barreto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisele S.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline C.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wania","family":"Pereira-Manfro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Hugo","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thalita F.","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina B.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl 3","key":"R3-11-20210202","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200406003-00002","article-title":"Antiretroviral treatment in resource-poor settings: the Brazilian experience.","volume":"18","author":"Teixeira","year":"2004","journal-title":"AIDS"},{"key":"R4-11-20210202","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(11)60202-X","article-title":"Successes and failures in the control of infectious diseases in Brazil: social and environmental context, policies, interventions, and research needs.","volume":"377","author":"Barreto","year":"2011","journal-title":"Lancet"},{"key":"R5-11-20210202","doi-asserted-by":"crossref","first-page":"e59768","DOI":"10.1371\/journal.pone.0059768","article-title":"Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era.","volume":"8","author":"Grinsztejn","year":"2013","journal-title":"PLoS One"},{"key":"R6-11-20210202","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/170.5.1279","article-title":"Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants.","volume":"170","author":"Dickover","year":"1994","journal-title":"J Infect Dis"},{"key":"R7-11-20210202","first-page":"279","article-title":"Invasive meningococcal disease and HIV coinfection.","volume":"25","author":"Couldwell","year":"2001","journal-title":"Commun Dis Intell"},{"key":"R8-11-20210202","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1128\/JCM.30.9.2290-2294.1992","article-title":"Neisseria spp. and AIDS.","volume":"30","author":"Morla","year":"1992","journal-title":"J Clin Microbiol"},{"key":"R9-11-20210202","doi-asserted-by":"crossref","first-page":"937","DOI":"10.7326\/0003-4819-123-12-199512150-00007","article-title":"Sporadic meningococcal disease in adults: results of a 5-year population-based study.","volume":"123","author":"Stephens","year":"1995","journal-title":"Ann Intern Med"},{"key":"R10-11-20210202","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1258\/0956462011923237","article-title":"Meningococcal infection in patients with the human immunodeficiency virus and acquired immunodeficiency syndrome.","volume":"12","author":"Pearson","year":"2001","journal-title":"Int J STD AIDS"},{"key":"R11-11-20210202","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/0035-9203(91)90380-H","article-title":"No association between meningococcal disease and human immunodeficiency virus in adults in Nairobi, Kenya.","volume":"85","author":"Brindle","year":"1991","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R12-11-20210202","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/infdis\/166.2.359","article-title":"Epidemic meningococcal disease in Nairobi, Kenya, 1989. The KenyaCenters for Disease Control (CDC) Meningitis Study Group.","volume":"66","author":"Pinner","year":"1992","journal-title":"J Infect Dis"},{"key":"R13-11-20210202","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1097\/00002030-199212000-00031","article-title":"Meningococcal meningitis and HIV infection: results from a case-control study in western Uganda.","volume":"6","author":"Kipp","year":"1992","journal-title":"AIDS"},{"key":"R14-11-20210202","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/QAD.0b013e32833a2520","article-title":"Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa (GERMS-SA). Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa.","volume":"24","author":"Cohen","year":"2010","journal-title":"AIDS"},{"key":"R15-11-20210202","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-160-1-201401070-00731","article-title":"Elevated risk for invasive meningococcal disease among persons with HIV.","volume":"160","author":"Miller","year":"2014","journal-title":"Ann Intern Med"},{"key":"R16-11-20210202","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1017\/S0950268812001689","article-title":"The epidemiology of meningococcal disease in Latin America 1945-2010: an unpredictable and changing landscape.","volume":"141","author":"Safadi","year":"2013","journal-title":"Epidemiol Infect"},{"key":"R17-11-20210202","first-page":"195","article-title":"A critical appraisal of the recommendations for the use of meningococcal conjugate vaccines.","volume":"88","author":"Safadi","year":"2012","journal-title":"J Pediatr (Rio J)"},{"key":"R19-11-20210202","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jama.286.6.694","article-title":"Invasive meningococcal disease in adolescents and young adults.","volume":"286","author":"Harrison","year":"2001","journal-title":"JAMA"},{"key":"R20-11-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe.","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"R22-11-20210202","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22399","article-title":"Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis.","volume":"56","author":"Zonneveld-Huijssoon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R23-11-20210202","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1016\/j.vaccine.2011.03.080","article-title":"Natural and vaccine-induced immunity to Neisseria meningitides serogroup C in asplenic patients with -thalassemia.","volume":"29","author":"Spoulou","year":"2011","journal-title":"Vaccine"},{"key":"R24-11-20210202","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2011.06.033","article-title":"Immunogenicity of conjugate meningococcus C vaccine in pediatric solid organ transplant recipients.","volume":"29","author":"Zlamy","year":"2011","journal-title":"Vaccine"},{"key":"R25-11-20210202","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1016\/j.vaccine.2012.06.069","article-title":"Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults.","volume":"30","author":"Bertolini","year":"2012","journal-title":"Vaccine"},{"key":"R27-11-20210202","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/01.inf.0000237830.33228.c3","article-title":"Pediatric AIDS Clinical Trials Group P1024 Protocol Team. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.","volume":"25","author":"Abzug","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R28-11-20210202","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1473-3099(04)01106-5","article-title":"Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children.","volume":"4","author":"Obaro","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"R29-11-20210202","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/00006454-200208000-00010","article-title":"Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.","volume":"21","author":"McVernon","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R30-11-20210202","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R31-11-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R32-11-20210202","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/314753","article-title":"Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.","volume":"179","author":"Richmond","year":"1999","journal-title":"J Infect Dis"},{"key":"R33-11-20210202","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R34-11-20210202","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1016\/S0264-410X(00)00050-5","article-title":"Immunogenicity and reactogenicity of group C meningococcal conjugate vaccine compare with a group AC meningococcal polysaccharide vaccine in adolescents in a randomized observer-blind controlled trial.","volume":"18","author":"Choo","year":"2000","journal-title":"Vaccine"},{"issue":"pt 9","key":"R35-11-20210202","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1099\/jmm.0.45529-0","article-title":"Neisseria meningitidis: an overview of the carriage state.","volume":"53","author":"Yazdankhah","year":"2004","journal-title":"J Med Microbiol"},{"key":"R36-11-20210202","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00006454-200204000-00011","article-title":"Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection.","volume":"21","author":"Madhi","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R37-11-20210202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/hv.18432","article-title":"Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.","volume":"8","author":"Nunes","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R38-11-20210202","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1468-1293.2011.00982.x","article-title":"Paediatric European Network for Treatment of AIDS (PENTA) Vaccines Group; PENTA Steering Committee; Childrens HIV Association (CHIVA). Guidance on vaccination of HIV-infected children in Europe.","volume":"13","author":"Menson","year":"2012","journal-title":"HIV Med"},{"key":"R41-11-20210202","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R42-11-20210202","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","article-title":"IMPAACT P1065 Protocol Team. Phase III, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.","volume":"29","author":"Siberry","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R43-11-20210202","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/INF.0b013e318236c67b","article-title":"IMPAACT P1065 Protocol Team. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.","volume":"31","author":"Siberry","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R44-11-20210202","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.04.005","article-title":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.","volume":"161","author":"Lujan-Zilbermann","year":"2012","journal-title":"J Pediatr"},{"key":"R45-11-20210202","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R46-11-20210202","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","article-title":"Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.","volume":"24","author":"Pichichero","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R47-11-20210202","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/IAI.72.10.5903-5909.2004","article-title":"Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.","volume":"72","author":"Welsch","year":"2004","journal-title":"Infect Immun"},{"key":"R48-11-20210202","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"R49-11-20210202","doi-asserted-by":"crossref","first-page":"e15924","DOI":"10.1371\/journal.pone.0015924","article-title":"A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers.","volume":"6","author":"Hunt","year":"2011","journal-title":"PLoS One"},{"key":"R50-11-20210202","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1097\/QAD.0000000000000007","article-title":"CD4 T-cell activation impairs serogroup C Neisseria meningitis vaccine response in HIV-infected children.","volume":"27","author":"Milagres","year":"2013","journal-title":"AIDS"},{"key":"R51-11-20210202","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0b013e318203e9f2","article-title":"Adolescent Medicine Trials Network for HIVAIDS Interventions (ATN). Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens.","volume":"56","author":"Flynn","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R52-11-20210202","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/INF.0b013e31816454a3","article-title":"Antibody response to hepatitis A immunization among human immunodeficiency virus-infected children and adolescents.","volume":"27","author":"Siberry","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R53-11-20210202","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1086\/505149","article-title":"Pediatric AIDS Clinical Trials Group 265 Team. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4() T cells.","volume":"194","author":"Levin","year":"2006","journal-title":"J Infect Dis"},{"key":"R54-11-20210202","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1086\/505077","article-title":"Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization.","volume":"194","author":"Vu","year":"2006","journal-title":"J Infect Dis"},{"key":"R55-11-20210202","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:06:19Z","timestamp":1620954379000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201505000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000630","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}